Despite a recent setback with a Parkinson's disease drug, Denali Therapeutics Inc. (NASDAQ: DNLI) has a significant $35.00 price target from Morgan Stanley, implying substantial 87.77% potential ...
Microsoft is heavily investing in artificial ...
Several companies, including Ideal Power, Sutro B...
Co-Diagnostics, Inc. (NASDAQ: CODX) surged due to a $3 million private placement, highlighting strong performance in the healthcare sector. CPS Technologies Corporation (NASDAQ: CPSH) saw significant
Copart (NASDAQ: CPRT) Delivers Strong Q3, Jefferies Adjusts Price Target Copart (NASDAQ: CPRT)'s third-quarter fiscal 2026 results showcased robust financial performance
National Bank reiterated an "Outperform" rating for CAE Inc. (NYSE:CAE) but adjusted its price target downward due to prevailing market challenges. Despite the price target reduction, CAE reported st
AnaptysBio, Inc. (NASDAQ:ANAB) demonstrates strong capital efficiency, with its Return on Invested Capital (ROIC) significantly higher than its Weighted Average Cost of Capital (WACC). The co
SI-BONE, Inc. (NASDAQ:SIBN) currently shows a negative Return on Invested Capital (ROIC) of -8.99% against a Weighted Average Cost of Capital (WACC) of 8.22%, indicating it's not yet generating v
Arm Holdings (NASDAQ:ARM) maintains a strong position in the semiconductor industry through its licensing model, bolstered by recent analyst upgrades and positive outlooks. Strategic partners
